21 – 30 of 38
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Molecular pathology of the luminal class of urothelial tumors
(
- Contribution to journal › Article
-
Mark
Re : Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol 2019;75:423–32
(
- Contribution to journal › Letter
-
Mark
Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival
(
- Contribution to journal › Article
- 2018
-
Mark
Molecular subtype classification of urothelial carcinoma in Lynch syndrome
(
- Contribution to journal › Article
-
Mark
A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort
(
- Contribution to journal › Article
-
Mark
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
(
- Contribution to journal › Article
-
Mark
Molecular Characterization of Bladder Cancer Subtypes
(
- Thesis › Doctoral thesis (compilation)
-
Mark
FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation
(
- Contribution to journal › Article
- 2017
-
Mark
HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
(
- Contribution to journal › Article
-
Mark
Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
(
- Contribution to journal › Debate/Note/Editorial